12/2
10:57 am
arqt
Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]
11/28
08:04 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.
11/27
01:47 pm
arqt
Tori Spelling And Daughter Stella Open Up About Struggles With Eczema [Forbes]
Low
Report
Tori Spelling And Daughter Stella Open Up About Struggles With Eczema [Forbes]
11/17
08:00 am
arqt
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
Medium
Report
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
11/13
08:38 am
arqt
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis [Yahoo! Finance]
Low
Report
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis [Yahoo! Finance]
11/13
08:00 am
arqt
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Low
Report
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
11/12
04:26 am
arqt
Arcutis Biotherapeutics (ARQT): Assessing Valuation After First Profitable Quarter and Raised Growth Outlook [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT): Assessing Valuation After First Profitable Quarter and Raised Growth Outlook [Yahoo! Finance]
11/7
04:24 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/7
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/4
08:00 am
arqt
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
Low
Report
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
11/1
01:04 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at
Wall S
Medium
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at
Wall S
10/31
07:14 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/30
10:59 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
10/30
09:32 am
arqt
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments [Yahoo! Finance
Low
Report
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments [Yahoo! Finance
10/30
09:15 am
arqt
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
Low
Report
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
10/30
08:00 am
arqt
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
Medium
Report
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
10/29
08:42 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $32.00 price target on by analysts at Mizuho.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $32.00 price target on by analysts at Mizuho.
10/29
07:10 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/28
05:23 pm
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $22.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $22.00 to $30.00. They now have a "buy" rating on the stock.
10/28
08:30 am
arqt
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
High
Report
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
10/27
04:00 pm
arqt
Arcutis to Present at Upcoming Investor Conferences
High
Report
Arcutis to Present at Upcoming Investor Conferences
10/24
08:00 am
arqt
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
Low
Report
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
10/6
08:49 am
arqt
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 [Yahoo! Finance]
Low
Report
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 [Yahoo! Finance]
10/6
08:00 am
arqt
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
Medium
Report
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
10/4
09:24 am
arqt
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest [Yahoo! Finance]